Interferon Gamma 1b as a treatment for macular edema caused by uveitis

Effects of topical interferon Gamma 1b in the treatment of uveitic cystoid macular edema

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105236568N1

Enrollment

Registered

2011-12-28

Start date

2011-03-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveitic cystoid macular edema. other specified retinal disorders, uveitis

Interventions

one drop of considered eye drop containing 10 micrograms in 0.05 ml of interferon Gamma 1b solution, weekly for 3 weeks will be instilled in involved eye(s).

Treatment - Drugs

one drop of considered eye drop containing 10 micrograms in 0.05 ml of interferon Gamma 1b solution, weekly for 3 weeks will be instilled in involved eye(s)

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (to have medial, posterior or pan-uveitis at least 3 months before the participation in the study together with macular cystoid edema secondary to uveitis in at least one eye; to have visual acuity equal or greater than 20/200; to be 18 to 60 year-old; to have a central macular thickness greater than 250 micrometers) Exclusion criteria: (pregnancy or breast feeding; occurrence of intolerable adverse effects; to have a history of herpetic kerititis and multiple sclerosis; to have an active infection which needs an urgent treatment; history of chronic or recurrent infections)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Central Macular Thickness. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Using Optical Coherence Tomography (OCT), micrometer.;Intraoccular pressure. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Using tonometer, mmHg.;Intraoccular inflammation. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Using slit lamp, mild or moderate or severe.	—

Measure

Time frame

Central Macular Thickness. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Using Optical Coherence Tomography (OCT), micrometer.;Intraoccular pressure. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Using tonometer, mmHg.;Intraoccular inflammation. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Using slit lamp, mild or moderate or severe.

—

Secondary

Measure	Time frame
Visual acuity. Timepoint: Before the initiation of the intervention, one week after instillation of each dose for 3 weeks, 3 months after the finishing of the study. Method of measurement: Snellen chart, in a fraction of 200.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadReza Eskandari

Tabriz Medical University

Mohammad.r.eskandari@gmail.com+98 41 1658 4305

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026